Investigational drug · Phase 2
KJ103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Anti-Glomerular Basement Membrane Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KJ103"
First trial start
2024
Oct 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KJ103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anti-Glomerular Basement Membrane Disease
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "KJ103" as an intervention, largest first.
Shanghai Bao Pharmaceuticals Co., Ltd.Industry
NCT05274659 · 34 participants · Start May 19, 2022 · Primary completion Mar 18, 2023
Drug: KJ103; Placebo · For: Healthy
Sites: Auckland, New Zealand
- A Clinical Trial With KJ103 in Anti-GBM DiseaseActive, not recruiting
Shanghai Bao Pharmaceuticals Co., Ltd.Industry
NCT06607016 · 12 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2025
Drug: KJ103 for Injection; Cyclophosphamide and 1 more · For: Anti-Glomerular Basement Membrane Disease
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials.
Cao M, Katial R, Liu Y, et al. · Gene Ther 2025
Also in development for Anti-Glomerular Basement Membrane Disease
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.